FDA Grants Breakthrough Therapy Status to Lenvima-Keytruda Combo for Advanced Liver Cancer
News
The U.S. Food and Drug Administration (FDA) has granted the designation of breakthrough therapy to Keytruda (pembrolizumab) in combination with Lenvima (lenvatinib) as a first-line treatment for patients with advanced unresectable ... Read more